General Information
Azacitidine is used to treat myelodysplastic syndromes (MDS), a number of disorders in which not enough healthy blood cells are produced in the bone marrow, leaving patients with low blood counts. In healthy bone marrow, stem cells become red blood cells, white blood cells or platelets. In MDS, this process is dysfunctional. In a significant portion of patients, MDS progresses to a rapidly growing cancer of bone marrow cells called acute myeloid leukemia.
About the API
Systematic name
4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one
Trade name(s)
Vidaza
Technology
High Potent
Molecular Formula
C8H12N4O5
Molecular Weight
244.20 g/mol
Physical properties
White to off- white powder
Therapeutic category
Oncology
Available formulations
Injectables
Regulations
EU DMF
US DMF